Iocanlidic acid I-123

Drug Profile

Iocanlidic acid I-123

Alternative Names: I-123 IPPA

Latest Information Update: 07 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer King Pharmaceuticals Research and Development; Nonindustrial source
  • Class Fatty acids; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery disease

Most Recent Events

  • 07 Jul 1999 Discontinued-III for Coronary artery disease (diagnosis) in USA (unspecified route)
  • 20 Feb 1997 Phase-III clinical trials for Coronary artery disease (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top